Abstracts by keywords: Opipramol
One of the biggest health policy challenges in the coming decades will be the increase in mental illnesses. From 2009 to 2010 alone, health insurance companies recorded an increase in the number of patients requiring treatment of 21.4 % [1]. According to forecasts, the number of patients will continue to increase in the future and, according to the World Health Organization, mental illness will be the second most common widespread disease in 2020 [2]. Consequently, the resulting effects on our healthcare system and, not least, the resulting costs are a central topic of discussion [3]. In Germany e.g. B. According to calculations by the Federal Institute for Occupational Safety and Health, direct costs of 16 billion euros per year (as of 2011) arise due to illnesses from the depressive form [4]. These are expected to double to 32 billion euros by 2030 [4]. One reason for this is, among other things, the increasing number of prescriptions of antidepressants. This increased by 7% between 2010 (1176 DDD = defined daily dose) and 2011 (1257 DDD) [5]. According to the German Society for Psychiatry and Psychotherapy, Psychosomatics and Neurology (DGPPN), this development will continue in the future. This can be explained by the fact that due to demographic change, an increase in older people is to be expected and they are often affected by depression [2].